The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER).
 
Tom Wei-Wu Chen
Honoraria - Daiichi Sankyo; Eisai; Lilly; Novartis; Roche
Consulting or Advisory Role - Blueprint Medicines; Daiichi Sankyo; Eisai
Research Funding - Eisai; Epizyme
Travel, Accommodations, Expenses - Eisai; Roche
 
Chih-Wei Yu
No Relationships to Disclose
 
Ruey-Long Hong
Research Funding - Lilly; MSD
 
Chueh-Chuan Yen
Honoraria - Amgen; Eisai; Lilly; Merck Sharp & Dohme
Consulting or Advisory Role - Lilly; Lilly; Merck Sharp & Dohme
Research Funding - Athenex (Inst); Deciphera (Inst); Efficient Pharma Management Corp. (Inst); Eisai (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Taiwan Liposome (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Ono Pharmaceutical; Roche
 
Jhe-Cyuan Guo
No Relationships to Disclose
 
San-Chi Chen
No Relationships to Disclose
 
Jen-chieh Lee
No Relationships to Disclose
 
Mei-Lu Chen
No Relationships to Disclose
 
Hsin-Fang Chang
No Relationships to Disclose
 
Meng-Chi Hsu
No Relationships to Disclose
 
Ting-Fang Kung
No Relationships to Disclose